Lupin Limited, an India-based global pharma company, announced on Wednesday that it has collaborated with US-based Mark Cuban Cost Plus Drug Company (Cost Plus Drugs), a company that deals with affordable medicines, and the COPD Foundation, an organisation dedicated to improving the lives of chronic obstructive pulmonary disease (COPD) patients.

The partnership intends to increase access to healthcare by increasing the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, to COPD patients in the US.

Presently, the company's Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, is the only generic product available that is therapeutically equivalent to Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule by Boehringer Ingelheim Pharmaceuticals, Inc.

Spiro Gavaris, president US Generics, Lupin, said, 'We believe there is a large unmet need for improved and affordable products for patients in the US. As a leading healthcare organisation, we are committed to increasing access for patients, seeking treatment options for respiratory conditions like COPD, with our respiratory portfolio and pipeline. Our collaboration with Mark Cuban Cost Plus Drug Company and the COPD Foundation reflects our intent to provide quality treatment options for patients.'